The utilization of obesity pharmacotherapies targeting glucagon-like peptide-1 receptors (GLP-1R) have had clinical success (7, 8) and are U.S. Food and Drug Administration (FDA)–approved for diabetes and obesity treatment (e.g., liraglutide and semaglutide). Here, GLP1R is linked to diabetes mellitus.